Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06361823
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-12
First Post:
2024-03-02
Brief Title:
Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment
Sponsor:
Capital Medical University
Organization:
Capital Medical University
Study Overview
Official Title:
An Exploratory Study Assessing the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to investigate the safety and efficacy of semaglutide in patients with Idiopathic intracranial hypertension
Detailed Description:
Idiopathic intracranial hypertension IIH is a condition characterized by elevated pressure within the skull for reasons that are not yet understood This condition does not involve abnormalities in the cerebrospinal fluid or any structural brain damage Individuals with this condition commonly experience persistent headaches and some may face the potential of irreversible vision loss significantly impacting their psychological well-being and overall quality of life At present the efficacy of medications like acetazolamide and topiramate in managing IIH is constrained by practical clinical constraints Recent studies have indicated that glucagon-like peptide-1 receptor agonists show promise as a potential treatment option for IIH Semaglutide as a long-acting glucagon-like peptide-1 formulation has a half-life of up to 160 hours and only needs to be injected once a week It is easy to administer and has good safety and tolerability Hence the objective of this study is to investigate the effectiveness and safety of semaglutide in managing idiopathic intracranial hypertension laying the groundwork for subsequent extensive multicenter research endeavors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None